Atropos Health Inc.

Atropos Health, Inc. is a US-based company that specializes in personalized Real-World Evidence (RWE), bridging gaps in evidence-based medical decision-making through advanced healthcare insights and data analytics. Founded in 2020 and headquartered in New York, Atropos Health, Inc. focuses on delivering cloud-based healthcare solutions.

The firm has completed a total of 4 deals, with the latest being a Series B funding round on May 20, 2024, in which they raised USD 33. 000 mn, led by Valtruis, along with participation from multiple investors including Breyer Capital and Merck Global Health Innovation Fund. The current company valuation stands at USD 130. 451 mn.

Atropos Health specializes in creating high-quality, personalized Real-World Evidence (RWE) aimed at bridging gaps in evidence-based medical decision-making. Their core offerings center around a cloud-based platform that integrates advanced data analytics with healthcare insights, allowing healthcare providers to generate publication-grade observational studies efficiently. Their clientele includes health systems, academic institutions, and pharmacy organizations, primarily in the United States, utilizing Atropos Health's technology to enhance formulary considerations, optimize patient throughput, and refine care management programs. Atropos Health generates revenue through a business-to-business model, primarily via subscription-based services and partnerships with healthcare providers and research institutions.

Clients access their platform for analytics and evidence generation, entering agreements that typically involve annual subscription plans. These plans grant users access to a comprehensive suite of tools, including the Atropos Evidence™ Network and proprietary evidence generation tools like ChatRWD® and GENEVA OS®. The structured pricing of these offerings aligns with the value delivered through enhanced patient outcomes and cost savings realized by clients. In May 2024, Atropos Health Inc.

raised USD 33. 000 mn in Series B funding, led by Valtruis, to support its expansion strategy. The company plans to develop and launch new products aimed at improving healthcare outcomes while targeting specific markets for geographic growth, although detailed timelines for these initiatives have not been disclosed. The recent funding will be utilized to propel these expansion plans and enhance their product offerings.